Pediatric Off-Patent Study Requests Will Not Mirror Rate For Exclusivity
Executive Summary
FDA does not expect to issue written requests for studies of off-patent drugs at the same rate it has for patented drugs seeking pediatric exclusivity, Office of Counterterrorism & Pediatric Drug Development Director Dianne Murphy, MD, said
You may also be interested in...
FDA Reorganization Creates Prominent Roles For Mercy Hospital's Spielberg, CDER's Autor
Commissioner Hamburg places drug, biologics, devices and tobacco centers under Steven Spielberg's directorate; Deborah Autor becomes deputy commissioner for global regulatory operations and policy.
FDA Refers Wellbutrin SR, Zyban To NIH For Pediatric Studies
FDA is requesting that the National Institutes of Health conduct pediatric studies on GlaxoSmithKline's bupropion agents Wellbutrin SR and Zyban
FDA Refers Wellbutrin SR, Zyban To NIH For Pediatric Studies
FDA is requesting that the National Institutes of Health conduct pediatric studies on GlaxoSmithKline's bupropion agents Wellbutrin SR and Zyban